The Role of Interferons in the Pathogenesis of Sjögren's Syndrome and Future Therapeutic Perspectives
- PMID: 33572487
- PMCID: PMC7916411
- DOI: 10.3390/biom11020251
The Role of Interferons in the Pathogenesis of Sjögren's Syndrome and Future Therapeutic Perspectives
Abstract
There is a great deal of evidence pointing to interferons (IFNs) as being key cytokines in the pathogenesis of different systemic autoimmune diseases, including primary Sjögren's syndrome (pSS). In this disease, a large number of studies have shown that an overexpression of type I IFN, the 'so-called' type I IFN signature, is present in peripheral blood mononuclear cells, and that this finding is associated with the development of systemic extra-glandular manifestations, and a substantial production of autoantibodies and inflammatory cytokines. In contrast, the absence or a milder expression of type I IFN signature and low level of inflammatory cytokines characterizes patients with a different clinical phenotype, where the disease is limited to glandular involvement and often marked by the presence of widespread pain and depression. The role of type II (IFNγ) in this subset of pSS patients, together with the potentially related activation of completely different immunological and metabolic pathways, are emerging issues. Expression of both types of IFNs has also been shown in target tissues, namely in minor salivary glands where a predominance of type II IFN signature appeared to have a certain association with the development of lymphoma. In view of the role played by IFN overexpression in the development and progression of pSS, inhibition or modulation of IFN signaling has been regarded as a potential target for the therapeutic approach. A number of therapeutic compounds with variable mechanisms of action have been tested or are under consideration for the treatment of patients with pSS.
Keywords: Sjögren’s syndrome; target therapies; type I interferon; type II interferon.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.J Autoimmun. 2015 Sep;63:47-58. doi: 10.1016/j.jaut.2015.07.002. Epub 2015 Jul 14. J Autoimmun. 2015. PMID: 26183766 Free PMC article.
-
Cytokine concentrations in stimulated whole saliva among patients with primary Sjögren's syndrome, secondary Sjögren's syndrome, and patients with primary Sjögren's syndrome receiving varying doses of interferon for symptomatic treatment of the condition: a preliminary study.Clin Oral Investig. 2001 Jun;5(2):133-5. doi: 10.1007/s007840100104. Clin Oral Investig. 2001. PMID: 11480812 Clinical Trial.
-
Mechanisms of Disease: primary Sjögren's syndrome and the type I interferon system.Nat Clin Pract Rheumatol. 2006 May;2(5):262-9. doi: 10.1038/ncprheum0173. Nat Clin Pract Rheumatol. 2006. PMID: 16932699 Review.
-
TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis.J Autoimmun. 2018 Jul;91:97-102. doi: 10.1016/j.jaut.2018.02.001. Epub 2018 Apr 16. J Autoimmun. 2018. PMID: 29673738
-
Type I IFN signature in primary Sjögren's syndrome patients.Expert Rev Clin Immunol. 2014 Apr;10(4):457-67. doi: 10.1586/1744666X.2014.876364. Epub 2014 Jan 22. Expert Rev Clin Immunol. 2014. PMID: 24450331 Review.
Cited by
-
Management of Sjögren's Syndrome: Present Issues and Future Perspectives.Front Med (Lausanne). 2021 Jun 7;8:676885. doi: 10.3389/fmed.2021.676885. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34164418 Free PMC article. Review.
-
Immunomodulatory Mechanism and Potential Application of Dental Pulp-Derived Stem Cells in Immune-Mediated Diseases.Int J Mol Sci. 2023 Apr 29;24(9):8068. doi: 10.3390/ijms24098068. Int J Mol Sci. 2023. PMID: 37175774 Free PMC article. Review.
-
Understanding Fatigue in Sjögren's Syndrome: Outcome Measures, Biomarkers and Possible Interventions.Front Immunol. 2021 Jun 25;12:703079. doi: 10.3389/fimmu.2021.703079. eCollection 2021. Front Immunol. 2021. PMID: 34249008 Free PMC article. Review.
-
Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways.Front Immunol. 2024 Sep 30;15:1437512. doi: 10.3389/fimmu.2024.1437512. eCollection 2024. Front Immunol. 2024. PMID: 39403378 Free PMC article.
-
Identification and Validation of IFI44 as a Novel Biomarker for Primary Sjögren's Syndrome.J Inflamm Res. 2024 Aug 28;17:5723-5740. doi: 10.2147/JIR.S477490. eCollection 2024. J Inflamm Res. 2024. PMID: 39219820 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical